Concept
Inflammation
Related people (78)
Johan Auwerx
Johan Auwerx is Professor at the École Polytechnique Fédérale in Lausanne, Switzerland, where he occupies the Nestle Chair in Energy Metabolism. Dr. Auwerx has been using molecular physiology and systems genetics to understand metabolism in health, aging and disease. Much of his work focused on understanding how diet, exercise and hormones control metabolism through changing the expression of genes by altering the activity of transcription factors and their associated cofactors. His work was instrumental for the development of agonists of nuclear receptors - a particular class of transcription factors - into drugs, which now are used to treat high blood lipid levels, fatty liver, and type 2 diabetes. Dr. Auwerx was amongst the first to recognize that transcriptional cofactors, which fine-tune the activity of transcription factors, act as energy sensors/effectors that influence metabolic homeostasis. His research validated these cofactors as novel targets to treat metabolic diseases, and spurred the clinical use of natural compounds, such as resveratrol, as modulators of these cofactor pathways.
Johan Auwerx was elected as a member of EMBO in 2003 and is the recipient of a dozen of international scientific prizes, including the Danone International Nutrition Award, the Oskar Minkowski Prize, and the Morgagni Gold Medal. His work is highly cited by his peers with a h-factor of over 100. He is an editorial board member of several journals, including Cell Metabolism, Molecular Systems Biology, The EMBO Journal, Journal of Cell Biology, Cell, and Science. Dr. Auwerx co-founded a handful of biotech companies, including Carex, PhytoDia, and most recently Mitobridge, and has served on several scientific advisory boards.
Dr. Auwerx received both his MD and PhD in Molecular Endocrinology at the Katholieke Universiteit in Leuven, Belgium. He was a post-doctoral research fellow in the Departments of Medicine and Genetics of the University of Washington in Seattle.
Nikolaos Stergiopoulos
Education
MTE, Managing the Technology Enterprise Program (2000), IMD, Lausanne
Ph.D. in Biomedical Engineering & Engineering Mechanics (1990) Iowa State University, Ames, Iowa.
MS in Biomedical Engineering (1987) Iowa State University, Ames, Iowa.
Diploma in Mechanical Engineering (1985) National Technical University of Athens.
Professional Activities
2002 - present: Professor and director of LHTC
2010 - present: Founder and director of Rheon Medical SA, Préverenges, Switzerland
2008 - present: Founder and director of Antlia S.A., PSE-C, EPFL campus, Switzerland
1998 - 2007: Founder and Scientific Director of EndoArt S.A., Lausanne, Switzerland
1996 - 2002: Assistant professor at the Biomedical Engineering Laboratory, Swiss Federal Institute of Technology, Lausanne, Switzerland.
1991 - 1996: Research Associate at Swiss Federal Institute of Technology - Lausanne
1990 - 1991: Lecturer, Iowa State University
Freddy Radtke
Freddy Radtke obtained his Ph.D. in Molecular Biology from the University of Zürich in 1994. In 1995, he started his postdoctoral research in the laboratory of Michel Aguet at Genentech, Inc. (San Francisco, USA). In 1997, he returned to Switzerland with Michel Aguet and finished his postdoctoral fellowship at the Swiss Institute for Experimental Cancer Research (ISREC) in Lausanne. From 1999‑2005, he was a group leader and Associate Member at the Ludwig Institute for Cancer Research. Freddy Radtke then joined ISREC in January 2006 as a senior scientist and in July 2006, he was appointed Associate Professor at the EPFL School of Life Sciences
Didier Trono
After obtaining an M.D. from the University of Geneva and completing a clinical training in pathology, internal medicine and infectious diseases in Geneva and at Massachusetts General Hospital in Boston, Didier Trono embarked in a scientific career at the Whitehead Institute for Biomedical Research of MIT. In 1990, he joined the faculty of the Salk Institute for Biological Studies to launch a center for AIDS research. He moved back to Europe seven years later, before taking the reins of the newly created EPFL School of Life Sciences, which he directed from 2004 to 2012. He is now actively engaged in the efforts of Switzerland to integrate new technologies in the fields of precision medicine and personalized health.
Sandro Carrara
Sandro Carrara is an IEEE Fellow for his outstanding record of accomplishments in the field of design of nanoscale biological CMOS sensors. He is also the recipient of the IEEE Sensors Council Technical Achievement Award in 2016 for his leadership in the emerging area of co-design in Bio/Nano/CMOS interfaces. He is a Professor of the EPFL in Lausanne (Switzerland), and head of the "Bio/CMOS Interfaces" (BCI) research group. He is former professor of optical and electrical biosensors at the Department of Electrical Engineering and Biophysics (DIBE) of the University of Genoa (Italy) and former professor of nanobiotechnology at the University of Bologna (Italy). He holds a PhD in Biochemistry & Biophysics from University of Padua (Italy), a Master degree in Physics from University of Genoa (Italy), and a diploma in Electronics from National Institute of Technology in Albenga (Italy). His scientific interests are on electrical phenomena of nano-bio-structured films, and include CMOS design of biochips based on proteins and DNA. Along his carrier, he published 7 books, one as author with Springer on Bio/CMOS interfaces and, more recently, a Handbook of Bioelectronics with Cambridge University Press. He has more than 250 scientific publications and is author of 13 patents. He is now Editor-in-Chief of the IEEE Sensors Journal, the largest journal among 2019 IEEE publications; he is also founder and Editor-in-Chief of the journal BioNanoScience by Springer, and Associate Editor of IEEE Transactions on Biomedical Circuits and Systems. He is a member of the IEEE Sensors Council and his Executive Committee. He was a member of the Board of Governors (BoG) of the IEEE Circuits And Systems Society (CASS). He has been appointed as IEEE Sensors Council Distinguished Lecturer for the years 2017-2019, and CASS Distinguished Lecturer for the years 2013-2014. His work received several international recognitions: several Top-25 Hottest-Articles (2004, 2005, 2008, 2009, and two times in 2012) published in highly ranked international journals such as Biosensors and Bioelectronics, Sensors and Actuators B, IEEE Sensors journal, and Thin Solid Films; a NATO Advanced Research Award in 1996 for the original contribution to the physics of single-electron conductivity in nano-particles; six Best Paper Awards at the IEEE Sensors Conference 2019 (Montreal) in 2019, Conferences IEEE NGCAS in 2017 (Genoa), MOBIHEALTH in 2016 (Milan), IEEE PRIME in 2015 (Glasgow), in 2010 (Berlin), and in 2009 (Cork); three Best Poster Awards at the EMBEC Conference in 2017 (Tampere, Finland), Nanotera workshop in 2011 (Bern), and NanoEurope Symposium in 2009 (Rapperswil). He also received the Best Referees Award from the journal Biosensor and Bioelectronics in 2006. From 1997 to 2000, he was a member of an international committee at the ELETTRA Synchrotron in Trieste. From 2000 to 2003, he was scientific leader of a National Research Program (PNR) in the filed of Nanobiotechnology. He was an internationally esteemed expert of the evaluation panel of the Academy of Finland in a research program for the years 2010-2013. He has been the General Chairman of the Conference IEEE BioCAS 2014, the premier worldwide international conference in the area of circuits and systems for biomedical applications
Jacques Fellay
Jacques Fellay is a medical scientist with expertise in infectious diseases and human genomics. He obtained his MD from the University of Lausanne in 2002 and his PhD from University of Utrecht. After a clinical training in infectious diseases in Switzerland and a 4-years postdoctoral fellowship at Duke University, he joined the EPFL in April 2011 with an SNF Professorship.
On top of his EPFL affiliation, Jacques is also Head of Precision Medicine at the University Hospital (CHUV) in Lausanne, Group Leader at the Swiss Institute of Bioinformatics, and Co-director of the Health2030 Genome Center at Campus Biotech in Geneva.